DBS analyst Nico Chen maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H today and set a price target of HK$33.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nico Chen has given his Buy rating due to a combination of factors including the company’s rapid scale-up in overseas markets and improving financial profile. MedBot’s flagship laparoscopic surgical robot, Toumai, has quickly become one of the top two products globally by order volume, with overseas orders and installations rising strongly and now contributing the bulk of total sales, supported by a clear cost advantage versus the leading competing system.
At the same time, losses are narrowing sharply as revenue grows and operating expenses fall as a percentage of sales, helped in part by more disciplined R&D spending and better cost control as the business scales. Chen expects the company to move toward breakeven around 2026, and he bases his HKD33.0 target price on a discounted cash flow valuation, citing accelerating overseas order momentum and the anticipated break-even point as key share price catalysts despite potential headwinds from global geopolitical tensions.
According to TipRanks, Chen is a 4-star analyst with an average return of 8.2% and a 53.73% success rate. Chen covers the Healthcare sector, focusing on stocks such as Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, Amgen, and AptarGroup.